Products | Radiopharmaceuticals and Tracers | August 20, 2015

DOTA-Zoledronate

DOTA-Zoledronate

Related Content

Proteus ONE compact proton therapy system
News | Proton Therapy
IBA signs contract with Yale New Haven Health and Hartford HealthCare to Install Proteus ONE Proton Therapy Solution

May 21, 2024 — IBA, a world leader in particle accelerator technology, announced that it has signed a contract with the ...

Time May 21, 2024
arrow
Registration is now open for #ASTRO24
News | ASTRO
American Society for Radiation Oncology (ASTRO) to Host Annual Meeting in Washington, DC, Sept. 29-Oct. 2

May 17, 2024 — Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting ...

Time May 17, 2024
arrow
Acquisition of Mariana Oncology brings together two companies at the forefront of novel radiopharmaceutical development, with a total potential value of up to $1.75 billion
News | Radiation Oncology
Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer

May 10, 2024 — Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical ...

Time May 10, 2024
arrow
POSLUMA (flotufolastat F 18) PET/CT image showing uptake in the prostate gland, consistent with primary prostate cancer.
News | Radiopharmaceuticals and Tracers
Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development

May 8, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 08, 2024
arrow
Extending beyond brain tumors, empowering patients with treatment options in prostate cancer and other malignancies
News | Prostate Cancer
GT Medical Technologies, Inc and Theragenics Corporation Forge Distribution Partnership for Cesium-131

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
SunCHECK Version 5.0 addresses clinical workflow challenges with new treatment plan assessment capabilities, enhanced TPS/OIS integration, expanded QA device control, and worklist-based UI.
News | Radiation Therapy
Sun Nuclear Announces Landmark Update to Further Advance Radiation Therapy Workflows

May 1, 2024 — Sun Nuclear, a Mirion Medical company, today announced the upcoming version 5.0 release of its SunCHECK ...

Time May 01, 2024
arrow
The study, led by principal investigator Nitin Ohri, M.D., a professor in Radiation Oncology at the Montefiore Einstein Comprehensive Cancer Center, aims to demonstrate the feasibility of PGHD collection during proton beam radiotherapy for lung cancer
News | Proton Therapy
Koneksa Announces Study with New York Proton Center to Collect Patient-Generated Health Data During Proton Radiotherapy in Lung Cancer

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
177Lutetium-labeled radiohybrid Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is in development as a highly optimized, next generation therapeutic radiopharmaceutical
News | Radiopharmaceuticals and Tracers
Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

April 10, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time April 10, 2024
arrow
Ga-68 has a very short half-life, which presents logistical challenges in distribution
News | Radiopharmaceuticals and Tracers
RLS Radiopharmacies Partners with Eckert and Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
During the blood pool phase, it significantly shortens the T1 and T2 relaxation times of the blood, thus achieving bright blood effects in T1-weighted imaging and dark blood effects in T2/T2*-weighted imaging. In the delay phase, by the local aggregation of ferumoxytol disrupting the uniformity of the local magnetic field, the decrease of the transverse magnetization vector Mxy is expedited, resulting in a negative contrast effect.
News | Molecular Imaging
Exploring Ferumoxytol: A Frontier in MRI Contrast Agents

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now